Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Metyrosine-associated endocrinological changes in pheochromocytoma and paraganglioma.
Matsuo Y, Ashida K, Nagayama A, Moritaka K, Gobaru M, Yasuda J, Ogasawara N, Kurose H, Chikui K, Iwata S, Inoguchi Y, Hasuzawa N, Motomura S, Igawa T, Nomura M. Matsuo Y, et al. Among authors: hasuzawa n. Endocr Oncol. 2023 Aug 29;3(1):e230006. doi: 10.1530/EO-23-0006. eCollection 2023 Jan 1. Endocr Oncol. 2023. PMID: 37822367 Free PMC article.
Metreleptin Supplementation for Improving Lipid and Glycemic Profiles in Acquired Diabetes Lipodystrophy: A Case Report.
Nagayama A, Ashida K, Moritaka K, Hidaka M, Gobaru M, Tanaka S, Hasuzawa N, Akasu S, Goto Y, Motomura S, Hara K, Tsuruta M, Wada N, Nakayama H, Tajiri Y, Nomura M. Nagayama A, et al. Among authors: hasuzawa n. J Endocr Soc. 2019 Sep 16;3(11):2179-2183. doi: 10.1210/js.2019-00251. eCollection 2019 Nov 1. J Endocr Soc. 2019. PMID: 31720553 Free PMC article.
Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy.
Nagayama A, Ashida K, Watanabe M, Moritaka K, Sonezaki A, Kitajima Y, Takahashi H, Yoshinobu S, Iwata S, Yasuda J, Hasuzawa N, Ozono S, Motomura S, Nomura M. Nagayama A, et al. Among authors: hasuzawa n. Front Endocrinol (Lausanne). 2021 May 31;12:690996. doi: 10.3389/fendo.2021.690996. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34135866 Free PMC article.
Effects of Elobixibat, an Inhibitor of Ileal Bile Acid Transporter, on Glucose and Lipid Metabolism: A Single-arm Pilot Study in Patients with T2DM.
Yoshinobu S, Hasuzawa N, Nagayama A, Iwata S, Yasuda J, Tokubuchi R, Kabashima M, Gobaru M, Hara K, Murotani K, Moriyama Y, Ashida K, Nomura M. Yoshinobu S, et al. Among authors: hasuzawa n. Clin Ther. 2022 Oct;44(10):1418-1426. doi: 10.1016/j.clinthera.2022.08.009. Epub 2022 Sep 16. Clin Ther. 2022. PMID: 36117045 Clinical Trial.
Human Leukocyte Antigen (HLA) Subtype-Dependent Development of Myasthenia Gravis, Type-1 Diabetes Mellitus, and Hashimoto Disease: A Case Report of Autoimmune Polyendocrine Syndrome Type 3.
Gobaru M, Ashida K, Yoshinobu S, Nagayama A, Kabashima M, Iwata S, Hasuzawa N, Tsuruta M, Wada N, Nakayama H, Motomura S, Tajiri Y, Nomura M. Gobaru M, et al. Among authors: hasuzawa n. Am J Case Rep. 2019 Nov 20;20:1709-1714. doi: 10.12659/AJCR.918996. Am J Case Rep. 2019. PMID: 31745069 Free PMC article.
An Open-label Phase I/IIa Clinical Trial of 11β-HSD1 Inhibitor for Cushing's Syndrome and Autonomous Cortisol Secretion.
Oda S, Ashida K, Uchiyama M, Sakamoto S, Hasuzawa N, Nagayama A, Wang L, Nagata H, Sakamoto R, Kishimoto J, Todaka K, Ogawa Y, Nakanishi Y, Nomura M. Oda S, et al. Among authors: hasuzawa n. J Clin Endocrinol Metab. 2021 Sep 27;106(10):e3865-e3880. doi: 10.1210/clinem/dgab450. J Clin Endocrinol Metab. 2021. PMID: 34143883 Clinical Trial.
Quinacrine is not a vital fluorescent probe for vesicular ATP storage.
Hasuzawa N, Moriyama S, Wang L, Nagayama A, Ashida K, Moriyama Y, Nomura M. Hasuzawa N, et al. Purinergic Signal. 2021 Dec;17(4):725-735. doi: 10.1007/s11302-021-09820-8. Epub 2021 Oct 28. Purinergic Signal. 2021. PMID: 34713379 Free PMC article.
31 results